
GLP-1 Miracle Faces Stigma: Doctors Respond to Trump's 'Fat Drug' Remarks
GLP-1 medications, used to treat diabetes, obesity and heart-related conditions, are increasingly common (about 11% of US adults, up from 3% in 2024). While many users and physicians praise their health benefits, President Trump’s labeling of GLP-1s as 'fat drugs' has drawn criticism for stigmatizing a lifesaving treatment; experts emphasize obesity’s complex causes and call for broader Medicaid coverage and policy action to improve access.



